Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zelboraf Tripped Up By Cost At NICE; Can Better Survival Estimates Save It?

This article was originally published in The Pink Sheet Daily

Executive Summary

Despite being convinced of its clinical effectiveness, NICE demands more data on Roche’s melanoma drug Zelboraf to prove its cost-effectiveness.

You may also be interested in...



Zelboraf And Yervoy Benefit From Secret Discounts To Pass NICE Barrier

NICE has recommended Roche’s Zelboraf and BMS’ Yervoy, as expected based partly on undeniable life extension capabilities, but also on secret price discounts offered by both manufacturers.

NICE Proves Cost Is Not Everything, Clears Two High-Priced Skin Cancer Drugs

Roche’s Zelboraf and Bristol-Myers Squibb’s Yervoy exceed NICE’s cost-effectiveness limit, but are still waved through as targeting unmet medical need.

Zelboraf Approval Hastened By FDA Officials Impressed With Early Efficacy

Supported by robust data demonstrating knock-out response rates, Roche/Genentech’s Zelboraf (vemurafenib) has sailed through the FDA approval process, aided by a push from the agency.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS074512

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel